Search hospitals > Idaho > Nampa
Saint Alphonsus Medical Center-Nampa
Claim this profileNampa, Idaho 83686
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Lung Cancer
Conducts research for Uterine Tumors
104 reported clinical trials
2 medical researchers
Summary
Saint Alphonsus Medical Center-Nampa is a medical facility located in Nampa, Idaho. This center is recognized for care of Cancer, Breast Cancer, Breast cancer, Lung Cancer, Uterine Tumors and other specialties. Saint Alphonsus Medical Center-Nampa is involved with conducting 104 clinical trials across 203 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
John M. SchallenkampBillings Clinic Cancer Center6 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
207 reported clinical trials
268 drugs studied
Benjamin T. MarchelloKalispell Regional Medical Center9 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
6 reported clinical trials
20 drugs studied
Clinical Trials running at Saint Alphonsus Medical Center-Nampa
Breast Cancer
Breast cancer
Multiple Myeloma
Cancer
Lung Cancer
Ovarian Cancer
Stomach Cancer
Esophageal Adenocarcinoma
Prostate Cancer
Fallopian Tube Cancer
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Sacituzumab Govitecan
for Brain Metastases from Breast Cancer
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.
Recruiting1 award Phase 212 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Alphonsus Medical Center-Nampa?
Saint Alphonsus Medical Center-Nampa is a medical facility located in Nampa, Idaho. This center is recognized for care of Cancer, Breast Cancer, Breast cancer, Lung Cancer, Uterine Tumors and other specialties. Saint Alphonsus Medical Center-Nampa is involved with conducting 104 clinical trials across 203 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.